Please login to the form below

Not currently logged in
Email:
Password:

New board appointments for UCB

Harriet Edelman and Charles-Antoine Janssen to join, as Belgian pharma confirms Karel Boone to step down as chair

UCB has said Harriet Edelman and Charles-Antoine Janssen will be appointed as board members on April 26 at the company's next general assembly.

The Belgium-based pharma firm also confirmed that Karel Boone will step down as chair, to be succeeded by fellow board member Gerhard Mayr. The decision was first announced in October, 2011.

Further changes include the resignation of Alexandre Van Damme from the board, as well the loss of Thomas Leysen and Gaëtan van de Werve, who have both come to the end of their mandates.

"Karel Boone, Thomas Leysen, Alexandre Van Damme and Gaëtan van de Werve have served very successfully as UCB board members and we would like to thank them for their key contribution and healthy challenges,” said Roch Doliveux, CEO of UCB.

“Special tribute and thanks go to Karel Boone, our chairman who has reached the statutory age limit. Karel has thoughtfully stimulated and supported UCB's transformation since 2000".

Mayr, who will take over as chair on April 26 as well, said of the most recent appointments: "We are delighted to have Harriet and Charles-Antoine as new candidates. Both bring unique experience and views to the board, enabling us to continue our journey as a patient-centric biopharma leader."

Edelman is currently vice chair of Emigrant Bank, and holds responsibility for finance operations and IT for New York Private Bank & Trust

Previously she was employed at beauty company Avon Products, serving in a number of leadership roles including senior VP and chief information officer and senior VP, global supply chain.

Janssen has been at UCB since 2001, holding several management positions at global and local levels.

Positions have included head of business development, general manager of Austria and India, and most recently managed international major markets operations.

Prior to UCB, he worked for Merrill Lynch in London from 1996-2000 where he was VP equities research then VP new derivatives Europe.

26th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics